Analytical Data
-
基因名
SUCLA2
- Application
-
别名
(ATP-specific succinyl-CoA synthetase subunit beta)(A-SCS)(Succinyl-CoA synthetase beta-A chain)(SCS-betaA)
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9P2R7
-
表达区间
53-463 aa
-
氨基酸序列
LSLHEYMSMELLQEAGVSVPKGYVAKSPDEAYAIAKKLGSKDVVIKAQVLAGGRGKGTFESGLKGGVKIVFSPEEAKAVSSQMIGKKLFTKQTGEKGRICNQVLVCERKYPRREYYFAITMERSFQGPVLIGSSHGGVNIEDVAAESPEAIIKEPIDIEEGIKKEQALQLAQKMGFPPNIVESAAENMVKLYSLFLKYDATMIEINPMVEDSDGAVLCMDAKINFDSNSAYRQKKIFDLQDWTQEDERDKDAAKANLNYIGLDGNIGCLVNGAGLAMATMDIIKLHGGTPANFLDVGGGATVHQVTEAFKLITSDKKVLAILVNIFGGIMRCDVIAQGIVMAVKDLEIKIPVVVRLQGTRVDDAKALIADSGLKILACDDLDEAARMVVKLSEIVTLAKQAHVDVKFQLPI
-
分子量
52 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SUCLA2, or succinate-CoA ligase, is a critical enzyme involved in the metabolism of succinate, playing a significant role in the tricarboxylic acid (TCA) cycle and energy production within mitochondria. Mutations in the SUCLA2 gene can lead to succinate-CoA ligase deficiency, which is associated with severe neurological disorders, including encephalopathy and developmental delays in children. These clinical manifestations emphasize the importance of understanding the functional mechanisms of SUCLA2 and its role in mitochondrial energy metabolism. Research into SUCLA2 recombinant proteins has gained traction as scientists seek to elucidate the enzyme’s structure-function relationships, investigate its catalytic properties, and develop potential therapeutic strategies for associated disorders. By producing recombinant SUCLA2, researchers can investigate the protein's biochemical characteristics, interactions with substrates, and response to various inhibitors. This knowledge is crucial for understanding the pathogenic mechanisms underlying SUCLA2-related diseases and could pave the way for novel treatment approaches. As mitochondrial dysfunction is increasingly recognized as a contributing factor to a wide array of disorders, the study of SUCLA2 and its recombinant form could lead to broader insights into metabolic diseases, mitochondrial biology, and potential therapeutic interventions.
